Burning Rock BiotechFRA:6BU0 +3.80%58 Gross Margin % is 72.27% as of Mar. 2026, which is 3% above its 10-year median of 70.26. GuruFocus rates FRA:6BU0 with a GF Score™ of 58/100 and a GF Value™ of €8.99 (Fairly Valued). The stock has 2 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Burning Rock Biotech ranks better than 79.9% on this metric.
The historical rank and industry rank for Burning Rock Biotech's Gross Margin % or its related term are showing as below:
FRA:6BU0'
s Gross Margin % Range Over the Past 10 Years
Min: 64.49 Med: 70.26 Max: 74.67
Current: 74.55
During the past 9 years, the highestGross Margin % of Burning Rock Biotech was 74.67%. The lowest was 64.49%. And the median was 70.26%.
FRA:6BU0's Gross Margin % is ranked better than 79.9% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 51.14
vs FRA:6BU0: 74.55
Burning Rock Biotech had a gross margin of 72.27% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Burning Rock Biotech was 0.20% per year.
Burning Rock Biotech (FRA:6BU0) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Burning Rock Biotech had a gross margin of 72.27% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Burning Rock Biotech Gross Margin % Related Terms
Burning Rock Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Burning Rock Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6BU0 vs XGN, IDXG, PRPO: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Burning Rock Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Burning Rock Biotech (FRA:6BU0) has a Gross Margin % of 72.27% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Burning Rock Biotech and its competitors. This is near median its historical median of 70.26. Over the past decade, Burning Rock Biotech's Gross Margin % has ranged from 64.49 to 74.67. According to the industry distribution chart, Burning Rock Biotech ranks #39 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 20.1%.
Is Burning Rock Biotech's Gross Margin % too high?
Burning Rock Biotech's current Gross Margin % of 72.27% is near median its 10-year median of 70.26. Over the past 10 years, this metric has ranged from a low of 64.49 to a high of 74.67. The Medical Diagnostics & Research industry median Gross Margin % is 51.14. Burning Rock Biotech's value of 72.27% is 41.3% above this industry median. Based on the distribution chart, Burning Rock Biotech ranks #39 out of 194 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Burning Rock Biotech has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Gross Margin % compare to XGN and IDXG?
According to the Medical Diagnostics & Research industry distribution chart, Burning Rock Biotech ranks #39 out of 194 companies for Gross Margin %. This places Burning Rock Biotech in the top 20% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 51.14. Burning Rock Biotech's value of 72.27% is 41.3% above this benchmark. Historically, Burning Rock Biotech's own Gross Margin % has ranged from 64.49 to 74.67 over the past decade. While the company's 10-year median is 70.26 vs. the industry median of 51.14, Burning Rock Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 51.14, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Burning Rock Biotech's current Gross Margin % of 72.27% is 41.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Burning Rock Biotech and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 51.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Burning Rock Biotech's current Gross Margin % is 72.27%, which is near median its own 10-year median of 70.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (FRA:6BU0) is currently considered Fairly Valued. The stock's GF Value™ is €8.99, compared to a current price of €8.20 — trading 8.8% below its estimated fair value. The current Gross Margin % is 72.27%, which is near median its 10-year median of 70.26 and 41.3% above the Medical Diagnostics & Research industry median of 51.14. Burning Rock Biotech's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Burning Rock Biotech (FRA:6BU0), the current Gross Margin % is 72.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be undervalued.
The current stock price of €8.20 is trading 8.8% below its estimated GF Value™ of €8.99.
GuruFocus considers Burning Rock Biotech to be Fairly Valued.
Key valuation signals for FRA:6BU0:
Gross Margin %: 72.27% (near median its 10-year median of 70.26)
GF Value™: €8.99 vs. price of €8.20 (8.8% below fair value)
Industry Position: 41.3% above the Medical Diagnostics & Research median (#39 of 194)
No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
58GF Score
Get the complete analysis for FRA:6BU0
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6BU0 has been successfully added to your 
